RVNC Revance Therapeutics
- 3.795
- +0.185+5.12%
- 3.810
- +0.015+0.40%
Revance Therapeutics News
Revance Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Jordan Erica
Revance Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-JPMORGAN CHASE & CO.(2.6%)
Revance Therapeutics | DEFA14A: Others
Revance Therapeutics | DEF 14A: Definitive information statements
Revance Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Sjuts Dustin S
Revance Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Moxie Dwight
Revance Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Schilke Tobin
Revance Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Foley Mark J
Revance Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Revance Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Revance Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Revance Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Foley Mark J
Revance Therapeutics | 8-K: Current report
Revance Therapeutics | 424B5: Prospectus
Revance Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Sjuts Dustin S
Revance Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Moxie Dwight
Revance Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Schilke Tobin
Revance Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Foley Mark J
Revance Therapeutics | 424B5: Prospectus
Revance Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Jordan Erica
Analysis
Price Target
No Data
